ARCUS BIOSCIENCES INCORPORATED (RCUS)

A board committee approved awards for 24 new employees July 27. One-quarter vests on or after one year; the rest vests quarterly, subject to continued employment.

Arcus Biosciences stock opened at $28.23 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -8.88 and a beta of 0.80. Arcus Biosciences has a 1 year low of $8.84 and a…

Arcus Biosciences (NYSE:RCUS) will be releasing its Q2 2026 earnings after the market closes on Wednesday, August 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-8-5-arcus-biosciences-inc-stock/)

The options carry a $29.73 exercise price, matching Arcus’s July 23 closing price; the awards were granted under the company’s 2020 Inducement Plan.

(NYSE:RCUS – Free Report) – Analysts at HC Wainwright cut their FY2029 earnings per share estimates for Arcus Biosciences in a research note issued on Monday, July 20th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($1.04) for the year, down from their…